益气温阳方联合化疗对结直肠癌晚期患者外周血Treg细胞影响研究

Effect of Yiqi Wenyang Decoction Recipe Combined with Chemotherapy on Treg Cells in Peripheral Blood of Patients with Advanced Colorectal Cancer

目的探讨益气温阳方联合化疗对晚期(ⅢⅣ期)结直肠癌患者外周血Treg细胞比率的影响及益气温阳方的抗癌机制。方法方便收集2017年01月-2018年06月收治的56例晚期结直肠癌患者,分为研究组及照组。对照组患者进行化疗,研究组患者在化疗基础上口服益气温阳方,两组患者均以21 d为一周期。利用流式细胞技术检测治疗前及治疗2周期后外周血CD4^+CD25^+CD127^low/-Treg细胞表达水平。结果对照组治疗后的外周血CD4^+CD25^+CD127^low/-Treg细胞比率较治疗前下降不明显[(5.51±0.87)%vs (5.03±1.21%],治疗前后差异无统计学意义(t=1.76,P>0.05),研究组治疗后的外周血CD4^+CD25^+CD127^low/-Treg细胞比率较治疗前下降明显[(5.59±1.45)%vs(4.28±1.23)%],差异有统计学意义(t=3.51,P<0.01),且研究组治疗后CD4^+CD25^+CD127^low/-Treg细胞比率明显低于对照组[(4.28±1.23)vs(5.03±1.21)],两组治疗后的组间比较,差异有统计学意义(t=2.29,P=0.02)。另研究组Treg细胞的抑制率明显高于对照组[(0.22±0.17)vs(0.09±0.13)],差异有统计学意义(t=3.18,P<0.01)。结论益气温阳方联合化疗能明显降低ⅢⅣ期结直肠癌患者外周血Treg细胞比率。通过降低Treg细胞水平,调节肿瘤免疫逃逸微环境来抑制肿瘤生长转移可能是益气温阳方扶正以抗癌的机制之一。

Objective To investigate the effect of Yiqi Wenyang Decoction combined with chemotherapy on the peripheral blood Treg cells of patients with late stage(ⅢⅣ) colorectal cancer. To investigate the anticancer mechanism of Yiqi Wenyang Decoction. Methods Convenient select a total of 56 patients with advanced colorectal cancer from January 2017 to June 2018 were collected. They were divided into control group and study group. The control group was given chemotherapy. The study group was given both Yiqi Wenyang Decoction and chemotherapy. The two groups were treated with 21 days as a treatment cycle. The expression level of CD4^+ CD25^+CD127^low/-Treg cells in peripheral blood was detected by flow cytometry before treatment and after 2 treatment cycles. Results The ratio of CD4^+ CD25^+CD127^low/- Treg cells in the peripheral blood of the control group was not significantly lower than that before treatment [(5.51±0.87)% vs(5.03±1.21%], which did not make significant difference between the ratio before treatment and the ratio after treatment(t=1.76, P>0.05). The ratio of CD4^+CD25^+CD127^low/- Treg cells in the peripheral blood of the study group was significantly lower than that before treatment [(5.59±1.45)% vs(4.28 ±1.23)%], which was statistically significant(t=3.51, P<0.01). And the ratio of CD4^+CD25^+ CD127^low/- Treg cells in the study group was significantly lower than that in the control group [(4.28±1.23) vs(5.03±1.21)], and the difference between the two groups after treatment was statistically significant(t=2.29, P=0.02). The inhibition rate of Treg cells in the study group was significantly higher than that in the control group [(0.22±0.17) vs(0.09±0.13)],which was statistically significant(t =3.18, P <0.01). Conclusion Yiqi Wenyang Decoction combined with chemotherapy could significantly decrease the peripheral blood Treg cells of patients with late stage(ⅢⅣ) colorectal cancer. Through decreasing the level of Treg cells and regulating tumor immune escape microenvironment to inhibit tumor growth may be one of the Yiqi Wenyang Decoction’s mechanisms of strengthening the body resistance to fight cancer.